

# Trelagliptin

## Catalog No: tcsc1041



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

**CAS No:**

865759-25-7

**Formula:**

$C_{18}H_{20}FN_5O_2$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

Dipeptidyl Peptidase

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 50$  mg/mL (139.91 mM)

**Alternative Names:**

SYR-472

**Observed Molecular Weight:**

357.38


## Product Description

Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).

IC50 value:

Target: DPP4

Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!